These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 16889993)

  • 1. Racial differences in the prevalence of Factor V Leiden mutation among patients on chronic warfarin therapy.
    Limdi NA; Beasley TM; Allison DB; Rivers CA; Acton RT
    Blood Cells Mol Dis; 2006; 37(2):100-6. PubMed ID: 16889993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Race-Specific Influence of CYP4F2 on Dose and Risk of Hemorrhage Among Warfarin Users.
    Shendre A; Brown TM; Liu N; Hill CE; Beasley TM; Nickerson DA; Limdi NA
    Pharmacotherapy; 2016 Mar; 36(3):263-72. PubMed ID: 26877068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quality of anticoagulation control and hemorrhage risk among African American and European American warfarin users.
    Limdi NA; Brown TM; Shendre A; Liu N; Hill CE; Beasley TM
    Pharmacogenet Genomics; 2017 Oct; 27(10):347-355. PubMed ID: 28806200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans.
    Limdi NA; Arnett DK; Goldstein JA; Beasley TM; McGwin G; Adler BK; Acton RT
    Pharmacogenomics; 2008 May; 9(5):511-26. PubMed ID: 18466099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Warfarin and cytochrome P450 2C9 genotype: possible ethnic variation in warfarin sensitivity.
    Kealey C; Chen Z; Christie J; Thorn CF; Whitehead AS; Price M; Samaha FF; Kimmel SE
    Pharmacogenomics; 2007 Mar; 8(3):217-25. PubMed ID: 17324110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of recurrent venous thromboembolism in patients with the factor V Leiden (FVR506Q) mutation: effect of warfarin and prediction by precipitating factors. East Anglian Thrombophilia Study Group.
    Baglin C; Brown K; Luddington R; Baglin T
    Br J Haematol; 1998 Mar; 100(4):764-8. PubMed ID: 9531346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ethnic distribution of factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening.
    Ridker PM; Miletich JP; Hennekens CH; Buring JE
    JAMA; 1997 Apr 23-30; 277(16):1305-7. PubMed ID: 9109469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of factor V G1691A (Leiden), prothrombin G20210A, and methylene tetrahydrofolate reductase C677T thrombophilic mutations in children with inflammatory bowel disease.
    Kader HA; Berman WF; Al-Seraihy AS; Ware RE; Ulshen MH; Treem WR
    J Pediatr Gastroenterol Nutr; 2002 Nov; 35(5):629-35. PubMed ID: 12454577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factor V Leiden as a common genetic risk factor for venous thromboembolism.
    Horne MK; McCloskey DJ
    J Nurs Scholarsh; 2006; 38(1):19-25. PubMed ID: 16579319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Race influences warfarin dose changes associated with genetic factors.
    Limdi NA; Brown TM; Yan Q; Thigpen JL; Shendre A; Liu N; Hill CE; Arnett DK; Beasley TM
    Blood; 2015 Jul; 126(4):539-45. PubMed ID: 26024874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapy.
    Limdi NA; Wiener H; Goldstein JA; Acton RT; Beasley TM
    Blood Cells Mol Dis; 2009; 43(1):119-28. PubMed ID: 19297219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The relationship of the factor V Leiden mutation and pregnancy outcomes for mother and fetus.
    Dizon-Townson D; Miller C; Sibai B; Spong CY; Thom E; Wendel G; Wenstrom K; Samuels P; Cotroneo MA; Moawad A; Sorokin Y; Meis P; Miodovnik M; O'Sullivan MJ; Conway D; Wapner RJ; Gabbe SG;
    Obstet Gynecol; 2005 Sep; 106(3):517-24. PubMed ID: 16135581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined factor V Leiden and prothrombin genotyping in patients presenting with thromboembolic episodes.
    Friedline JA; Ahmad E; Garcia D; Blue D; Ceniza N; Mattson JC; Crisan D
    Arch Pathol Lab Med; 2001 Jan; 125(1):105-11. PubMed ID: 11151062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective screening for the Factor V Leiden mutation: is it advisable prior to the prescription of oral contraceptives?
    Schambeck CM; Schwender S; Haubitz I; Geisen UE; Grossmann RE; Keller F
    Thromb Haemost; 1997 Dec; 78(6):1480-3. PubMed ID: 9423798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of the factor V leiden mutation in children and neonates with thromboembolic disease.
    Hagstrom JN; Walter J; Bluebond-Langner R; Amatniek JC; Manno CS; High KA
    J Pediatr; 1998 Dec; 133(6):777-81. PubMed ID: 9842043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factor V Leiden mutation is a risk factor for cerebral venous thrombosis: a case-control study of 55 patients.
    Lüdemann P; Nabavi DG; Junker R; Wolff E; Papke K; Buchner H; Assmann G; Ringelstein EB
    Stroke; 1998 Dec; 29(12):2507-10. PubMed ID: 9836759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors influencing warfarin dose requirements in African-Americans.
    Momary KM; Shapiro NL; Viana MA; Nutescu EA; Helgason CM; Cavallari LH
    Pharmacogenomics; 2007 Nov; 8(11):1535-44. PubMed ID: 18034618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Factor V Leiden and prothrombin G20210-->A mutations on thromboembolic risk in the national surgical adjuvant breast and bowel project breast cancer prevention trial.
    Abramson N; Costantino JP; Garber JE; Berliner N; Wickerham DL; Wolmark N
    J Natl Cancer Inst; 2006 Jul; 98(13):904-10. PubMed ID: 16818854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New genetic variant that might improve warfarin dose prediction in African Americans.
    Schelleman H; Brensinger CM; Chen J; Finkelman BS; Rieder MJ; Kimmel SE
    Br J Clin Pharmacol; 2010 Sep; 70(3):393-9. PubMed ID: 20716240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The Bavarian Thromboembolic Risk Cohort Study (BATER). Study protocol, state of the investigation and first results].
    Schramm W; Heinemann LA; Spannagl M; Dick A; Assmann A
    Dtsch Med Wochenschr; 2000 Jan; 125(1-2):2-6. PubMed ID: 10650817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.